AnaptysBio 10-Q: $3.9M Q3 Income, $153M Cash, GSK Royalty Case Awaits Ruling
ANAB has more than doubled off its 52-week low of $21.93.
Summary
AnaptysBio's Q3 10-Q confirms $3.9 million of net income on $30.3 million of collaboration revenue, $153.0 million of cash and investments, and a still-pending Delaware ruling that could return dostarlimab rights to the company.
Key Events · Earnings and Guidance · ANAB
-
Q3 Income of $3.9 Million
Net income from continuing operations was $3.876 million, or $0.13 per basic share, on collaboration revenue of $30.274 million, down from $76.320 million a year ago when a $50.0 million GSK sales milestone was recognized.
-
Cash Covers 12 Months, Royalty Debt $249.8M
Cash, cash equivalents and investments totaled $153.0 million at September 30, 2026, versus $164.1 million at June 30, 2026; the liability for sold future royalties stood at $249.819 million after $18.742 million of non-cash interest expense in the quarter.
-
GSK Litigation Awaits Ruling
Post-trial argument in the Tesaro/GSK Delaware Chancery case was held October 20, 2026; AnaptysBio asked the court to enforce the reversion provision and order return of dostarlimab rights. G&A included $4.8 million of related legal expense in the quarter.
-
$100M Buyback Unused, Expires Dec 31
The 2026 Repurchase Program authorized in March 2026 still had the full $100.0 million available at September 30, 2026 and expires December 31, 2026.
Analysis · ANAB · Life Sciences
The headline numbers were already out via this morning's 8-K, but the full 10-Q is where the balance sheet and legal risk live. After the April 2026 spin-off of First Tracks, AnaptysBio now runs on royalty cash flows, and it ended September with $153.0 million in cash and investments against a $249.8 million royalty liability owed to Sagard. Quarterly income of $3.9 million is thin relative to the $18.7 million of non-cash interest that the Sagard monetization generates each quarter, so reported profit depends heavily on Jemperli royalty growth. The bigger swing factor is the Delaware Chancery case: post-trial argument was held October 20, 2026, and AnaptysBio has asked the court to enforce the reversion provision and order Tesaro to return dostarlimab rights. A ruling in its favor would reset the entire revenue base; a loss leaves the current royalty stream intact but caps the upside. Separately, the $100 million buyback remains fully unused and expires December 31, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $47.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $21.93 to $72.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.